EMA Authorised: Balversa (Erdafitinib) — Janssen-Cilag International N.V.

View source ↗

Summary

The European Medicines Agency authorised Balversa (erdafitinib) for urothelial carcinoma of the bladder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma of the Bladder

Drugs mentioned

• BALVERSA (erdafitinib)

Snippet

Status: Authorised. Therapeutic area: Urologic Neoplasms. MAH: Janssen-Cilag International N.V.. Decision date: 18/02/2025